Table 4 Breakdown of costs. Discounted annual costs in $m over 50 years ^

From: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa

 

No lenacapavir + cabotegravir introduction

Lenacapavir-cabotegravir introduction

ART drug (len-cab)

3.35(0)

3.71 (1.29)

Cotrimoxazole

0.27

0.27

ART clinic visits

1.23

1.73

Viral load tests

1.13

1.15

CD4 count tests

0.05

0.05

Clinical disease care costs HIV-related

0.62

0.53

Pre-death care (non-HIV)

0.26

0.26

HIV testing

1.52

1.51

PrEP drug

0.67

0.65

PrEP clinic visits

0.58

0.57

VMMC

0.36

0.36

Condom availability

0.71

0.72

Care for children with HIV

0.31

0.23

Total

11.07

11.74

  1. ^ In the context of a setting with population size of 1 million adults aged 15+ in 2024; for a setting with x.x million adults the number can be multiplied by x.x.
Back to article page